Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04209153
Other study ID # APHP190731
Secondary ID 2019-A01946-51
Status Recruiting
Phase
First received
Last updated
Start date November 29, 2021
Est. completion date May 29, 2025

Study information

Verified date November 2021
Source Assistance Publique - Hôpitaux de Paris
Contact Florence THIBAUT, PHD
Phone (33) 1 58 41 16 79
Email florence.thibaut@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In summary, there are currently many therapeutic tools for achieving some degree of control or even cessation of tobacco addictive use. No single therapy seems to have proven itself sufficiently effective to be the preferred treatment axis in the management of this addiction. We can also point out that so far the main treatments aimed at reducing or controlling the craving phenomenon are of a pharmacological nature, thus exposing the participants to the side effects inherent to this type of treatment. In this perspective, the establishment of non invasive brain stimulation (TdCS), acting in a targeted manner on craving and whose effects would be mild and transient, appears quite justified, especially in addition to psychotherapy. In the context of the management of addictive pathologies, the choice of smoking dependence seems relevant to us insofar as this addiction represents a major public health problem.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 29, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women over the age of 18 - Nicotine dependent subjects according to the Fagerström test (score =5) - Subjects consuming daily tobacco. - Subjects understanding and reading French and able to express themselves in this language. - Signed informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and agrees to participate in the study and to comply with the requirements and limitations of this study - Affiliation to the French social security scheme or beneficiary of such a scheme. - No other method to decrease or stop smoking at the same time as the study. Exclusion Criteria: - Guardianship - Pregnant or lactating woman - Patient under AME - Subject being in the exclusion period of another study or provided for by the "National Volunteer File". - Subjects with intracranial hypertension - Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator. - Treatment with buproprion or varenicline in progress - Episode or family history of epilepsy, convulsion. - Disease causing damage to the brain (aneurysm, tumor, ...). - Cochlear or ocular implant. - Stimulator or cardiac defibrillator. - Presence of metal in the skull (clip on aneurysm, prosthesis, ...). - Eczema on the scalp.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Transcranial Direct Current Stimulation
tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics

Locations

Country Name City State
France Psychiatrie Adultes Et Addictologie Paris IDF

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fagerström score (3 is the highest score and O the lowest one for item 1. A score of 1 or 2 means low dependence (for item 1 only as well as if you use the total score) average difference in Fagerström score 1 scores that assess craving for tobacco between pre-treatment assessment (J0) and short-term post-treatment evaluations (J15). 15 days
Secondary tobacco consumption Evaluation of changes in tobacco consumption and smoking craving intensity and tolerance of tDCS 15 days